Flu vaccines released for 2012/2013 season

Vaccines for the current flu season are now available.

The JCVI has advised that where a flu vaccine dose of either 0.25ml or 0.5ml is recommended in children, those aged six months or older should be given the 0.5ml dose.  | SCIENCE PHOTO LIBRARY
The JCVI has advised that where a flu vaccine dose of either 0.25ml or 0.5ml is recommended in children, those aged six months or older should be given the 0.5ml dose. | SCIENCE PHOTO LIBRARY

The vaccines are: Enzira (Pfizer), Fluarix (GlaxoSmithKline), Fluvirin (Novartis), Imuvac and Influvac (Abbott), Inactivated Influenza Vaccine BP and Intanza (Sanofi-Pasteur MSD), and the live-attenuated intranasal preparation Fluenz (AstraZeneca), for use only in children and adolescents.

Agrippal and Optaflu (Novartis), Inflexal V and Viroflu (Janssen-Cilag) are expected to be available later in October.

The cell-culture-derived vaccine, Preflucel, is no longer available.

New strains

In line with EMA/WHO recommendations for the 2012/2013 season, the vaccines contain the same H1N1-like virus strain as last season (A/California/7/2009), with two new strains:

•    A/Victoria/361/2011 as the H3N2-like component
•    B/Wisconsin/1/2010 as the influenza B component.

Further information: Green Book – Chapter 19: Influenza

Follow MIMS on Twitter

Updated 1 November 2012

Prescribing information for egg-free vaccine released

Novartis has released 2012/2013 prescribing information for its flu vaccines Agrippal and Optaflu, but reports that both preparations are currently out of stock.

Optaflu is produced by cell culture rather than egg-based methods, making it suitable for individuals who are hypersensitive to egg or chicken proteins. It is licensed for use only in adults. As no other egg-free vaccine is currently available, the Department of Heath advises that patients with uncontrolled asthma who have confirmed anaphylaxis to egg or egg allergy should be referred to a specialist for vaccination in hospital.

Inflexal V and Viroflu are also unavailable as manufacturer Crucell has halted deliveries in order to investigate two batches on patient safety grounds. Prescribing information has not yet been released.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...

Novel MS drug gains NICE approval

Novel MS drug gains NICE approval

New NICE guidance recommends ocrelizumab (Ocrevus)...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

NICE recommends new triple therapy option for diabetes

NICE recommends new triple therapy option for diabetes

Ertugliflozin (Steglatro) can now be prescribed routinely...